ResearchMoz

Global Diabetes Devices Market And Diabetes Drugs Market - Industry Scenario, Trends, Analysis, Size, Share & Forecast 2011 - 2018

Transparency Market Research
Published Date » 2012-10-01
No. Of Pages » 162
   
 This report is an effort to identify factors, which will be the driving force behind the diabetes devices and drugs market and sub-markets in the nextfew years. Thereport provides extensive analysis of the industry, current market trends, industry drivers and challenges for better understanding of the market structure. The report has segregated the diabetes devices and drugs industry in terms of productand geography. We have used a combination of primary and secondary research to arrive at the market estimates, market shares and trends. We have adopted bottom up model to derive market size of the global diabetes devices and drugs market and further validated numbers with the key market participants and C-level executives.  
   
  This report highlights the industry with the...
TABLE OF CONTENTS

CHAPTER 1 PREFACE
1.1 REPORT DESCRIPTION
1.2 SCOPE OF THE REPORT
1.3 METHODOLOGY
1.4 ASSUMPTIONS

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 GLOBAL DIABETES MARKET ANALYSIS
3.1 DIABETES: AGE-GROUP ANALYSIS
3.2 MARKET OVERVIEW
3.3 KEY MARKET TRENDS
3.4 GLOBAL DIABETES MARKET SIZE AND FORECAST, 2010 – 2018
3.4.1 TYPE I DIABETES MARKET SIZE AND FORECAST
3.4.2 TYPE II DIABETES MARKET SIZE AND FORECAST
3.4.3 DIABETES DEVICES MARKET SIZE AND FORECAST
3.4.4 DIABETES DRUGS MARKET SIZE AND FORECAST
3.5 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)
3.6 MARKET DYNAMICS
3.6.1 DRIVERS
3.6.1.1 Growing Diabetic Population around the Globe
3.6.1.2 Changing Lifestyle and Obesity as a Leading Cause of Diabetes
3.6.1.3 Launch of New Generation Innovative Drugs Likely to Attract Consumers
3.6.2 RESTRAINTS
3.6.2.1 Lack of Awareness about Diabetes Diagnostics and Treatment
3.6.2.2 Adverse side-effects of drugs and the resulting litigation issues
3.6.3 OPPORTUNITIES
3.6.3.1 Increasing Awareness may Unleash the Untapped Market
3.7 IMPACT OF REGULATIONS ON TYPE II DIABETES MARKET GROWTH
3.7.1 RISE IN THE NUMBER OF BACKLOG OF DRUGS UNDER FDA REVIEW AND THE SHIFTING TIMELINES FOR THE SAME IN THE UNITEDSTATES
3.7.2 REGULATORS’ LAY MORE EMPHASIS ON ADEQUATE SAFETY DATA INSTEAD OF RELYING ONLY ON EFFICACY DATA FOR DRUG APPROVAL AND NEW DIRECTIVES FOR PATIENT SCREENING IN THE UNITED STATES
3.7.3 PROMOTION OF LOW-COST GENERICS TO LIMIT HEALTHCARE COSTS, HEALTHCARE INSURERS’ AND REGULATORS’
3.7.4 IN EMERGING MARKETS SUCH AS ASIA, PRICING CONTROLS ARE LIKELY TO BE PUT IN PLACE
3.8 FACTORS AFFECTING GLOBAL DIABETES DEVICES AND DRUGS MARKET
3.8.1 RISING INCIDENCE OF DIABETES IN KEY MARKETS SUCH AS U.S., U.K. AND GERMANY
3.8.2 RISING EDUCATION IS EXPECTED TO DECREASE DIABETES PREVALENCE BY 1.2%
3.8.3 PEOPLE WITH A DIABETES PARENT LEADS TO AN INCREASE OF 1.4%
3.8.4 SOCIAL FACTORS AFFECTING DIABETE
3.9 PORTERS FIVE FORECES ANALYSIS OF DIABETES DEVICES AND DRUGS MARKET 
3.9.1 BUYERS’ POWER
3.9.2 SUPPLIERS’ POWER
3.9.3 EXISTING RIVALRY
3.9.4 THREAT OF NEW ENTRANTS
3.9.5 THREAT OF SUBSTITUTE 
3.10 GLOBAL DIABETES DRUGS AND DEVICES REGULATORY SCENARIO

CHAPTER 4 GLOBAL DIABETES DEVICES AND DRUGS MARKET
4.1 GLOBAL DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE2010 – 2018
4.1.1 BLOOD GLUCOSE MONITORING DEVICES, MARKET SIZE AND FORECAST
4.1.1.1 Lancets
4.1.1.2 Blood Sampling Devices
4.1.1.3 Blood Glucose Monitors
4.1.1.3.1 Drivers
4.1.1.3.1.1 Increasing awareness and simpler devices
4.1.1.3.1.2 Increase in disposable income
4.1.1.3.1.3 Declining prices
4.1.1.3.1.4 Improving compatibility
4.1.1.3.2 Restraints
4.1.1.3.2.1 Increase in competition leading to low prices
4.1.1.3.2.2 Private label brands
4.1.1.3.2.3 Awareness among patients is still a challenge
4.1.1.3.3 Key trends
4.1.1.4 New Development in Glucose Testing
4.1.2 OTHER TESTING DEVICES MARKET SIZE AND FORECAST
4.1.2.1 Hemoglobin A1c
4.1.2.1.1 Hemoglobin A1c Meters
4.1.2.1.2 Hemoglobin A1c Kits
4.1.2.2 Others
4.1.3 SOFTWARE PROGRAMS FOR DIABETES MONITORING, MARKET SIZE AND FORECAST
4.1.3.1 Web Software Programs for Diabetes Monitoring
4.1.3.2 Commercial Software
4.1.4 ARTIFICIAL PANCREAS, MARKET SIZE AND FORECAST
4.2 GLOBAL DIABETES THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2011 – 2018
4.2.1 DRIVERS
4.2.1.1 Improved Delivery Devices
4.2.1.2 Increased Risk with Oral Anti-Diabetes Drugs
4.2.1.3 Technological Advancement
4.2.2 RESTRAINTS
4.2.2.1 Associated Pain
4.2.2.2 Market boom for New Generation diabetic drugs
4.2.2.3 Cost Issues
4.2.3 OPPORTUNITIES
4.2.3.1 Novel insulin delivery method
4.2.4 GLOBAL ORAL DIABETES DRUG MARKET
4.2.4.1 Popular Anti-Diabetic Drugs World wide
4.2.4.2 Drivers
4.2.4.2.1 Novel drugs driving the market growth
4.2.4.2.2 Patent expiry of popular drugs
4.2.4.2.3 Painless Option
4.2.5 RESTRAINTS
4.2.5.1 Associated high risks
4.2.5.2 Improving options of insulin delivery devices
4.2.5.3 Trend of diabetic diet
4.2.6 OPPORTUNITIES
4.2.6.1 Diabetes Vaccines
4.2.6.2 Leveraging the patent expiry of popular drugs
4.2.7 INSULIN, MAKET SIZE AND FORECAST 
4.2.7.1 Market Size and Forecast
4.2.7.2 Global Insulin Market Share of Major Players, 2011 
4.2.7 2.1 Global Human Insulin Market Share of Major Players, 2011 
4.2.7 2.2 Global Modern Insulin Market Share of Major Players, 2011
4.2.7.3 Insulin Market Size and Forecast, By Action
4.2.7.3.1 Short Acting
4.2.7.3.2 Pre-Mixes
4.2.7.3.3 Long Acting
4.2.7.4 Insulin Market Size and Forecast, by Type
4.2.7.4.1 Human Insulin
4.2.7.4.2 Modern Insulin
4.2.7.4.3 Animal Insulin
4.2.7.5 Insulin Market Size and Forecast, by Purchase Type
4.2.7.5.1 Dosage
4.2.7.5.2 Bulk
4.2.8 INSULIN, DELIVERY MAKET SIZE AND FORECAST
4.2.8.1 Insulin Syringes Maket Size and Forecast 
4.2.8.2 Insulin Pens Maket Size and Forecast
4.2.8.3 Insulin Injectors Maket Size and Forecast 
4.2.8.4 Inhaled Insulin Maket Size and Forecast 
4.2.8.5 Insulin Pumps Maket Size and Forecast 
4.2.8.5.1 Drivers
4.2.8.5.1.1 Growing Diabetic Population
4.2.8.5.1.2 Advancement in Technology
4.2.9 ORAL HYPOGLYCEMIC AGENTS, MAKET SIZE AND FORECAST
4.2.9.1 KATP Blocker Maket Size and Forecast
4.2.9.2 Biguanides Maket Size and Forecast 
4.2.9.3 Alpha-Glucosidase Inhibitor Maket Size and Forecast 
4.2.9.4 Thiazolinediones/ Glitazones Maket Size and Forecast 
4.2.9.5 Incretin Mimetics/ GLP-1 Analogs Maket Size and Forecast 
4.2.9.6 DPP-4 InhibitorMaket Size and Forecast 
4.2.9.7 Amylin Mimetic Maket Size and Forecast 
4.2.9.8 SGLT2 Inhibitors Maket Size and Forecast 
4.2.9.9 Other Oral Hypoglycemic Agents Maket Size and Forecast 
4.2.10 CELL THERAPIES MAKET SIZE AND FORECAST

CHAPTER 5 GEOGRAPHY ANALYSIS
5.1 GLOBAL OVERVIEW
5.2 EUROPE DIABETES DEVICES AND DRUGS MARKET
5.2.1 INNOVATION DRIVING THE EUROPEAN MARKET
5.2.1.1 Undiagnosed patients high in European countries
5.2.1.2 Increasing R&D costs
5.2.2 RESTRAINTS
5.2.2.1 Case1
5.2.2.2 Case 2
5.2.2.3 Case 3
5.2.3 OPPORTUNITIES
5.2.3.1 Undiagnosed Diabetic Patient Population in Europe
5.2.4 EUROPE DIABETES MARKET SHARE OF MAJOR PLAYERS
5.2.5 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST 
5.2.5.1 Blood glucose monitoring devices, maket size and forecast
5.2.5.2 Other dibetes testing devices, maket size and forecast
5.2.5.3 Software programs for diabetes monitoring, maket size and forecast
5.2.5.4 Artificial pancreas, maket size and forecast
5.2.6 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST
5.2.6.1 Insulin, maket size and forecast
5.2.6.2 Insulin delivery, maket size and forecast
5.2.6.3 Oral hypoglycemic agents, maket size and forecast
5.2.6.4 Cell therapies, maket size and forecast
5.3 ASIA PACIFIC DIABETES DEVICES AND DRUGS MARKET
5.3.1 CHINA
5.3.2 INDIA
5.3.3 SOUTH KOREA
5.3.4 TAIWAN
5.3.5 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST 
5.3.5.1 Blood glucose monitoring devices, maket size and forecast
5.3.5.2 Other dibetes testing devices, maket size and forecast
5.3.5.3 Software programs for diabetes monitoring, maket size and forecast
5.3.5.4 Artificial pancreas, maket size and forecast
5.3.6 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST
5.3.6.1 Insulin, maket size and forecast
5.3.6.2 Insulin delivery, maket size and forecast
5.3.6.3 Oral hypoglycemic agents, maket size and forecast
5.3.6.4 Cell therapies, maket size and forecast
5.4 NORTH AMERICA DIABETES DEVICES AND DRUGS MARKET 
5.4.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST
5.4.1.1 Blood glucose monitoring devices, maket size and forecast
5.4.1.2 Other dibetes testing devices, maket size and forecast
5.4.1.3 Software programs for diabetes monitoring, maket size and forecast
5.4.1.4 Artificial pancreas, maket size and forecast  
5.4.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST
5.4.2.1 Insulin, maket size and forecast
5.4.2.2 Insulin delivery, maket size and forecast
5.4.2.3 Oral hypoglycemic agents, maket size and forecast
5.4.2.4 Cell therapies, maket size and forecast
5.5 MIDDLE EAST AND AFRICA DIABETES DEVICES AND DRUGS MARKET 
5.5.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST  
5.5.1.1 Blood glucose monitoring devices, maket size and forecast
5.5.1.2 Other dibetes testing devices, maket size and forecast
5.5.1.3 Software programs for diabetes monitoring, maket size and forecast
5.5.1.4 Artificial pancreas, maket size and forecast 
5.5.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST 
5.5.2.1 Insulin, maket size and forecast
5.5.2.2 Insulin delivery, maket size and forecast
5.5.2.3 Oral hypoglycemic agents, maket size and forecast
5.5.2.4 Cell therapies, maket size and forecast 
5.6 LATIN AMERICDIABETES DEVICES AND DRUGS MARKET 
5.6.1 DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST 
5.6.1.1 Blood glucose monitoring devices, maket size and forecast
5.6.1.2 Other dibetes testing devices, maket size and forecast
5.6.1.3 Software programs for diabetes monitoring, maket size and forecast
5.6.1.4 Artificial pancreas, maket size and forecast 
5.6.2 THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST 
5.6.2.1 Insulin, maket size and forecast
5.6.2.2 Insulin delivery, maket size and forecast
5.6.2.3 Oral hypoglycemic agents, maket size and forecast
5.6.2.4 Cell therapies, maket size and forecast

CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 SUMMARY
6.2 MARKET SHARE OF MAJOR PLAYERS: GLOBAL DIABETES MARKET
6.3 GLOBAL DIABETES DEVICES MARKET SHARE OF MAJOR PLAYERS
6.4 GLOBAL DIABETES THERAPEUTIC MARKET SHARE OF MAJOR PLAYERS
6.4.1 INSULIN DELIVERY MARKET PLAYERS
6.4.2 GLOBAL DIABETES DRUGS MARKET SHARES OF MAJOR PLAYERS
6.5 CLINICAL TRIALS
6.6 RECENT DEVELOPMENTS
6.7 COMPETITIVE STRATEGY BY KEY PLAYERS

CHAPTER 7 COMPANY PROFILE
7.1 ABBOTT LABORATORIES
7.1.1 COMPANY OVERVIEW
7.1.2 REVENUE SHARE
7.1.3 RECENT DEALS
7.2 BRISTOL-MYERS SQUIBB (BMS)
7.2.1 COMPANY OVERVIEW
7.2.2 REVENUE SHARE
7.2.3 RECENT DEALS
7.3 DEXCOM
7.3.1 COMPANY OVERVIEW
7.3.2 REVENUE SHARE
7.3.3 RECENT DEALS
7.4 ELI LILLY
7.4.1 COMPANY OVERVIEW
7.4.2 REVENUE SHARE
7.4.3 RECENT DEALS
7.5 GLAXOSMITHKLINE
7.5.1 COMPANY OVERVIEW
7.5.2 REVENUE SHARE
7.5.3 RECENT DEALS
7.6 GLENMARK PHARMACEUTICALS
7.6.1 COMPANY OVERVIEW
7.6.2 REVENUE SHARE
7.6.3 RECENT DEALS
7.7 JOHNSON&JOHNSON
7.7.1 COMPANY OVERVIEW
7.7.2 REVENUE SHARE
7.7.3 RECENT DEALS
7.8 LUPIN
7.8.1 COMPANY OVERVIEW
7.8.2 REVENUE SHARE
7.8.3 RECENT DEALS
7.9 ROCHE
7.9.1 COMPANY OVERVIEW
7.9.2 REVENUE SHARE
7.9.3 RECENT DEALS
7.10 SANOFI
7.10.1 COMPANY OVERVIEW
7.10.2 REVENUE SHARE
7.10.3 RECENT DEALS

List of Tables

LIST OF TABLES

TABLE 1 OBESITY RATE IN THE U.S., BY STATE 2011 (%)
TABLE 2 CLINICAL TRIALS: US (ORAL ANTI-DIABETES DRUGS)
TABLE 3 CLINICAL TRIALS: CHINA (ORAL ANTI-DIABETES DRUGS)
TABLE 4 CLINICAL TRIALS: JAPAN (ORAL ANTI-DIABETES DRUGS)
TABLE 5 CLINICAL TRIALS: INDIA (ORAL ANTI-DIABETES DRUGS)
TABLE 6 CLINICAL TRIALS: UNITED KINGDOM (ORAL ANTI-DIABETIC DRUGS)
TABLE 7 CLINICAL TRIALS: GERMANY (ORAL ANTI-DIABETIC DRUGS)
TABLE 8 CLINICAL TRIALS: FRANCE (ORAL ANTI-DIABETIC DRUGS)
TABLE 9 CLINICAL TRIALS: US (ANTI-DIABETIC INJECTABLES)
TABLE 10 CLINICAL TRIALS: JAPAN (ANTI-DIABETIC INJECTABLES)
TABLE 11 CLINICAL TRIALS: CHINA (ANTI-DIABETIC INJECTABLES)
TABLE 12 CLINICAL TRIALS: INDIA (ANTI-DIABETIC INJECTABLES)
TABLE 13 CLINICAL TRIALS: GERMANY (ANTI-DIABETIC INJECTABLES)
TABLE 14 CLINICAL TRIALS: UNITED KINGDOM (ANTI-DIABETIC INJECTABLES)
TABLE 15 CLINICAL TRIALS: GERMANY (ANTI-DIABETIC INJECTABLES)
TABLE 16 GLOBAL DIABETES DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY GEOGRAPHY 2012 – 2018
TABLE 17 EUROPE DIABETES MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)
TABLE 18 EUROPE  DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE2012 – 2018 (USD MILLION)
TABLE 19 EUROPE DIABETES THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)
TABLE 20 ASIA PACIFIC DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 21 ASIA PACIFIC  DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPEBY TYPE, 2012 – 2018 (USD MILLION)
TABLE 22 ASIA PACIFIC THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 23 NORTH AMERICA DIABETES MARKET SIZE AND FORECAST, BY TYPE 2012 – 2018 (USD MILLION)
TABLE 24 NORTH AMERICA  DIABETES DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPEBY TYPE, 2012 – 2018 (USD MILLION)
TABLE 25 NORTH AMERICA THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA DIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA THERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 29 LATIN AMERICA DIABETES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 30 LATIN AMERICADIAGNOSIS AND MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 31 LATIN AMERICATHERAPEUTICS DEVICES AND DRUGS MARKET SIZE AND FORECAST, BY TYPE, 2012 – 2018 (USD MILLION)
TABLE 32 CLINICAL TRIALS: UNITED STATES (INSULIN PUMPS)
TABLE 33 CLINICAL TRIALS: UNITED KINGDOM (INSULIN PUMPS)
TABLE 34 CLINICAL TRIALS: FRANCE (INSULIN PUMPS)
TABLE 35 CLINICAL TRIALS: GERMANY (INSULIN PUMPS)
TABLE 36 CLINICAL TRIALS: CHINA (INSULIN PUMPS)
TABLE 37 CLINICAL TRIALS: UNITED STATES (GLUCOSE MONITORS)
TABLE 38 CLINICAL TRIALS: UNITED KINGDOM (GLUCOSE MONITORS)
TABLE 39 CLINICAL TRIALS: FRANCE (GLUCOSE MONITORS)
TABLE 40 CLINICAL TRIALS: CHINA (GLUCOSE MONITORS)

List of Figures

LIST OF FIGURES

FIG. 1 GLOBAL PREVALENCE OF DIABETES AMONG VARIOUS AGE GROUPS
FIG. 2 GLOBAL DIABETES PREVELANCE, BY COUNTRY 2011
FIG. 3 DRUGS VS. DEVICES MARKET SHARE
FIG. 1 GLOBAL DIABETES DEVICES AND DRUGS MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)
FIG. 2 TYPE-I DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 3 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 4 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 5 TYPE-II DIABETES MARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 6 GLOBAL INSULIN DEMAND GROWTH TREND, 2011 - 2018 (%)
FIG. 7 COUNTRY WISE DIABETES PATIENTS FORECAST, BY 2030 (MILLION)
FIG. 8 NUMBER OF DIABETES DRUGS IN DEVELOPMENT BY PHASE UNITED STATES, 2012
FIG. 9 NUMBER OF PEOPLE LEFT UNDIAGNOSED IN U.S., 2011 (MILLIONS)
FIG. 10 GLOBAL DIABETES DIAGNOSIS AND MONETORING MARKET SIZE AND FORECAST, BY CATEGORY 2010 - 2018 (USD MILLION)
FIG. 11 BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 12 LANCETS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 13 BLOOD SAMPLING BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 14 MARKET SHARES (U.S. VS OTHERS)
FIG. 15 MARKET SHARE OF SMBG TESTING IN THE INVITRO- DIAGNOSTIC MARKET GLOBALLY
FIG. 16 BLOOD GLUCOSE METERS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 17 NEW DEVELOPMENTS IN GLUCOSE TESTING BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 18 OTHER TESTING DEVICES BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 19 HEMOGLOBIN A1C BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 20 HEMOGLOBIN A1C METERS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 21 HEMOGLOBIN A1C KITS BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 22 OTHER A1C BLOOD GLUCOSE MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 23 SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 24 WEB SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 25 COMMERCIAL SOFTWARE PROGRAMS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 26 ARTIFICIAL PANCREAS FOR DIABETES MONITORING DEVICES MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 27 MARKET SHARE
FIG. 28 GLOBAL DIABETES THERAPEUTICS DEVICES AND DRUGS MARKETMARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 29 GLOBAL INSULINMARKET SIZE AND FORECAST, 2010 – 2018 (USD MILLION)
FIG. 30 GLOBAL INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011
FIG. 31 GLOBAL MODERN INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011
FIG. 32 GLOBAL HUMAN INSULIN MARKET SHARE OF MAJOR PLAYERS, 2011
FIG. 33 SHORT ACTING INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)
FIG. 34 PRE-MIXES INSULIN MARKET SIZE AND FORECAST, BY ACTION 2010 - 2018 (USD MILLION)
FIG. 35 LONG ACTING INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)
FIG. 36 HUMAN INSULIN MARKET SIZE AND FORECAST, 2010 - 2018 (USD MILLION)
FIG. 37 HUMAN INSULIN MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 38 HUMAN INSULIN MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 39 INSULIN MARKET DOSAGE SIZE AND FORECAST, BY PURCHASE TYPE 2010 - 2018 (USD MILLION)
FIG. 40 INSULIN MARKET BULK SIZE AND FORECAST, BY PURCHASE TYPE 2010 - 2018 (USD MILLION)
FIG. 41 GLOBAL INSULIN DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 42 INSULIN SYRINGES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 43 INSULIN PENS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 44 INSULIN INJECTORS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 45 INHALED INSULIN DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 46 INSULIN PUMPS MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 47 KEY PARTICIPANTS: MARKET SHARES (2011)
FIG. 48 ORAL HYPOGLYCEMIC AGENTS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 49 KATP BLOCKER MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 50 BIGUANIDES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 51 ALPHA-GLUCOSIDASE INHIBITOR DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 52 THIAZOLINEDIONES/ GLITAZONES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 53 INCRETIN MIMETICS/ GLP-1 ANALOGS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 54 DPP-4 INHIBITORS MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 55 AMYLIN MIMETIC DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 56 SGLT2 INHIBITORS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 57 OTHER ORAL HYPOGLYCEMIC AGENTS DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 58 CELL THERAPIES DELIVERY MARKET SIZE AND FORECAST, BY TYPE 2010 - 2018 (USD MILLION)
FIG. 59 DIABETES PREVALENCE IN EUROPE
FIG. 60 POPULATION DISTRIBUTION WITH DIABETES (INITIATING DPP-IV, TZD,  GLP-1 OR INSULIN)
FIG. 61 UNDIAGNOSED DIABETIC POPULATION
FIG. 62 EUROPEAN DIABETES DRUGS MARKET SHARE (2012)
FIG. 63 DISTRIBUTION OF DIABETES DRUG MARKET IN EUROPE
FIG. 64 DIABETES PREVALENCE IN ASIAN COUNTRIES
FIG. 65 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)
FIG. 66 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)
FIG. 67 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)
FIG. 68 GLOBAL DIABETES MARKET SHARE OF MAJOR PLAYERS, 2012 (%)
FIG. 69 MARKET SHARE OF ABBOTT LABORATORIES
FIG. 70 REVENUE SHARES OF ABBOTT LABORATORIES
FIG. 71 REVENUE TRENDS OF DEXCOM
FIG. 72 REVENUE TRENDS OF ELI LILLY
FIG. 73 REVENUE CONTRIBUTIONOF ELI LILLY
FIG. 74 REVENUE TREND OF GLAXOSMITH
FIG. 75 REVENUE TREND OF GLAXOSMITH
FIG. 76 REVENUE TREND OF GLENMARK PHARMACEUTICALS
FIG. 77 REVENUECONTRIBUTION OF JOHNSON&JOHNSON
FIG. 78 REVENUE TREND OF JOHNSON&JOHNSON
FIG. 79 REVENUE TREND OF LUPIN
FIG. 80 REVENUE TREND OF ROCHE
FIG. 81 REVENUE CONTRIBUTION OF SANOFI
FIG. 82 REVENUE TREND OF SANOFI

Upcoming Reports:

Vibrio Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Vibrio is a genus of anaerobic, non-spore forming, gram-negative bacteria that are curved rod shape. All the species of the vibrio genus are motile pathogens and have flagella with sheaths. Several species of these bacteria are capable of causing various conditionssuch as cholera, gastroenteritis, primary septicemia, cell necrosis and otitis. The following are some of the diagnostic techniques used for the detection of various diseases associated with vibrio: Enzyme Immunoassays (EIA) PCR Flow Cytometry Monoclonal Antibodies Diagnostic Imaging Immuno-PCR...
Turbine Gearbox For Thermal Power Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth And Forecast 2014 - 2020
By - Transparency Market Research
Rapid rise in demand for energy and increased modernization of aged thermal plants is expected to bolster the demand for turbine gearbox for thermal power market. Rise in demand for energy is attributed to the increase in the population worldwide. The increase in the demand for thermal power is likely to increase the demand for thermal power equipment as well. Additionally, easy availability of coal reserves and natural gas is anticipated to fuel demand for the global turbine gearbox for thermal power market. Installations of machines and turbines are likely to augment the demand for...
Thermal Energy Storage (TES) Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Thermal energy storage (TES) stores excess thermal energy in a storage medium and supplies it back in later use. TES can be utilized on an individual, multiuser, district or even on larger scale.TES systems provide balance between day time and night time or summer time and winter time. TES is commonly used in air conditioning activities of commercial buildings, where heat is stored during cooling cycles and recovered during heating cycles. It also helps in energy saving hence, TES makes air conditioning process sustainable. TES can also be accompanied by solar power. With the help of...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...